Transdermal Drug Delivery Systems Market: Growing Preference for Transdermal Drug Delivery Systems Create Widespread Opportunities for the Key Players

Surge in population across the world has given way to a steep increase in demand for geriatric medications and treatments. At the same time, the number of patient pool suffering from chronic syndromes such as arthritis, heart ailments, and diabetes has also amplified to a significant extent. These factors have escalated the adoption of transdermal drug delivery systems in more than one way.

According to Allied Market Research, the global market is anticipated to cite a remarkable CAGR from 2021 to 2030. The ongoing research & development activities and increasing acceptance of these expedients have facilitated the growth of the transdermal drug delivery systems market for years to come. As for example, the U.S FDA had come up with a new act for Adlarity, a weekly transdermal patch, in early 2021, for the treatment of individuals suffering from dementia.

Request Sample of the Report on Transdermal Drug Delivery Systems Market Forecast 2030 - https://www.alliedmarketresearch.com/request-sample/485

On the other hand, soaring demand for self-administration of medications has been highly beneficial for the growth of the market. For instance, individuals with diabetes call for long-standing treatment, since insulin has to be headed up through the patient's body with the aid of injections in a persistent mode. And, the increasing patient preference, over the last decade, for pain-free drug management has given way to a considerable rise in the adoption rate of cohesive skin patches that administer medicines.

In keeping with the Department of Economic & Social Affairs, United Nations, in the year 2017, the total number of individuals aged sixty years and above was more than nine-hundred million, which is beyond twice as huge as it was back in 1980. Moreover, the number of geriatric population is projected to get even twofold by the year 2050, almost reaching more than two billion, which in turn is projected to increase the count of geriatric diseases, thus impacting the transdermal drug delivery systems market positively.

According to Department of Economic and Social Affairs, United Nations, the total number of people aged 60 years and above was 962 million in 2017, which is more than twice as large as it was in 1980 when there were around 382 million globally. Furthermore, the number of older persons is expected to double again by 2050, nearly reaching 2.1 billion. This s expected to propel the demand for geriatric diseases, thereby positively influencing the transdermal drug delivery systems market. According to Centers for Disease Control and Prevention, an entity of the U.S. Department of Health & Human Services, 6 in every 10 American adults have a chronic disease and 4 in every 10 American adults have two or more chronic diseases. This has significantly increased the spending on healthcare services. According to the U.S. Centers for Medicare & Medicaid Services, the U.S. healthcare spending reached $4.1 trillion or $12,530 per person, witnessing a rise of 9.7%, and accounting for 19.7% of GDP in the U.S. in 2020.

As per Centers for Disease Control & Prevention, six in every ten adults in the United States tend to have chronic health syndromes and four in every ten individuals suffer from two or more chronic issues. This has considerably amplified the expenditure on healthcare services. Moreover, as stated by the U.S. Centers for Medicare and Medicaid Services, the overall healthcare outlays in America accounted for more than four trillion dollar, garnering a surge of almost ten percent and contributing to above nineteen percent of GDP in 2020 in the United States.

The transdermal drug delivery systems market witnessed significant growth in the past decade, owing to increase in number of patients suffering from chronic diseases and rapid growth of the pharmaceutical industry. A number of players in the transdermal drug delivery systems market are expanding their business to strengthen their foothold in the global market. By type of delivery, the passive segment dominated the transdermal drug delivery systems market in 2020, in terms of revenue. This is attributed to rise in increased spending on healthcare facilities. Depending on application, the motion sickness segment is expected to grow at a higher CAGR during the forecast period, owing to rise in number of travelers.

For Procurement Information - https://www.alliedmarketresearch.com/purchase-enquiry/485

Key Market Players:

Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co. Inc., Bayer AG, Johnson & Johnson, Novartis AG, Purdue Pharma L.P., Viatris Inc., Boehringer Ingelheim GmbH, Altaris

Comprehensive Healthcare Industry Research Studies: -

Microkeratome Market https://www.alliedmarketresearch.com/microkeratome-market

Microsurgery Market https://www.alliedmarketresearch.com/microsurgery-market-A131277

blood bank freezer market https://www.alliedmarketresearch.com/blood-bank-freezer-market-A134887

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of 'Market Research Reports' and 'Business Intelligence Solutions'. AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

This release was published on openPR.